Rome-based startup Sense4Med has successfully secured €510k in funding from investors such as Innova Venture and Scientifica Venture Capital. A spin-off from the University of Tor Vergata, the company specializes in pioneering point-of-care devices for diagnosing cystic fibrosis, a severe genetic condition impacting the respiratory and digestive systems.
Under the leadership of CEO Fabiana Arduini, a distinguished full professor of Analytical Chemistry, Sense4Med is committed to streamlining the cystic fibrosis diagnostic process with its innovative paper-based electrochemical biosensors. This technology offers the promise of swift and non-invasive disease detection through a sweat test, suitable for individuals of all ages and physical conditions. The secured funding will fuel the expansion of operations and advance the device’s development toward commercialization.
[Sign up here to never miss these candid conversations delivered straight to your inbox.]
